Candida Fratazzi MD
Founder & President
Boston Biotech Clinical Research
Candida Fratazzi, Executive MD, specialist in Orphan Indications, Immunology, Inflammation, and Oncology, over 18-year experience in drug development from pre-clinical through POC studies for small and large molecules. Dr. Fratazzi has extensive experience on the preparation of Orphan Petitions for rare diseases and orphan sub-populations within non-orphan diseases. Dr. Fratazzi has developed innovative clinical regulatory strategies and trial design for several successful medicinal products many of which as orphan drugs.
Candida Fratazzi devised the concept of a Strategic Clinical Innovation Organization (SCIO) and founded the first SCIO –Boston Biotech Clinical Research (BBCR), LLC in 2009, with the objective of actively contributing to innovation in streamlining clinical research and developing strategic clinical regulatory pathways to product approval. http://www.bbcrconsulting.com/